JNJ vs URGN: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

JNJ is the larger of the two ($651.09B market cap): the incumbent the market prices for continued execution (23.29x forward earnings, beta 0.20). URGN is the smaller challenger ($1.55B), cheaper on forward earnings (12.67x): more room to run, but more to prove. On the numbers, URGN leads on both counts: faster expected revenue growth (67% vs 6%) and a lower forward P/E (12.67x vs 23.29x). The case for JNJ rests on its own driver (Innovative Medicine pipeline): if you believe in that, JNJ fits; if you believe in what the numbers show today, URGN does.

JNJ vs URGN: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricJNJURGNWhat it tells you
Market cap$651.09B$1.55BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E23.2912.67Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.201.64Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range78% of range44% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Reading it: URGN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how JNJ and URGN affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. JNJ and URGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined JNJ and URGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Johnson & Johnson (JNJ) do?

Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Its Innovative Medicine segment develops and sells branded prescription drugs across oncology, immunology, neuroscience, cardiovascular, and other areas, with major franchises that drive much of its profit. Its MedTech segment makes medical devices and surgical equipment for cardiovascular intervention, orthopedics, surgery, and vision care. J&J makes money by researching, manufacturing, and selling patented pharmaceuticals and devices to hospitals, physicians, pharmacies, and patients worldwide, supported by one of the largest research and development budgets in healthcare. The company is known for its diversification, financial strength, AAA-class balance sheet, and a multi-decade record of raising its dividend, making it a classic defensive blue chip. Founded in 1886 and headquartered in New Brunswick, New Jersey, J&J is a broadly held, large-cap healthcare company valued for stability, income, and a deep drug and device pipeline.

Full JNJ guide

What does UroGen Pharma (URGN) do?

UroGen Pharma (Nasdaq: URGN) develops and sells drugs that treat urothelial cancers without surgery. Its core technology is RTGel, a reverse-thermal hydrogel that is liquid when cold and turns to gel at body temperature, which lets a chemotherapy agent sit against tumor tissue in the bladder or upper urinary tract long enough to work. Two products built on it are approved. Jelmyto, cleared in 2020, treats low-grade upper tract urothelial cancer. Zusduri, cleared in June 2025, treats recurrent low-grade intermediate-risk non-muscle invasive bladder cancer and is the first FDA-approved alternative to repeated transurethral resection surgery for that population. Behind them sit UGN-103 (a reformulated follow-on whose NDA the FDA accepted in October 2026, with a June 14, 2027 PDUFA target date), UGN-104 in upper tract disease, and UGN-501, an oncolytic virus that dosed its first Phase 1 patient in November 2026. The company has about 300 employees and is run by CEO Liz Barrett.

Full URGN guide

JNJ vs URGN: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • JNJ drivers: Innovative Medicine pipeline; MedTech innovation and recovery.
  • URGN drivers: The Zusduri launch curve; Operating leverage arriving faster than expected.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: J&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue. For URGN, the company still runs a shareholders' deficit of ~$125M, with ~$90.5M of cash and marketable securities against ~$196M of term debt and a prepaid forward obligation to RTW, and liquidity fell from ~$120.5M at the end of 2025.

JNJ or URGN: which should you pick?

If the story you believe is JNJ's (Innovative Medicine pipeline), JNJ is the more direct way to own it; if it is URGN's (The Zusduri launch curve), URGN is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the JNJ and URGN guides.

JNJ vs URGN: the full fundamentals

JNJ. J&J's trailing P/E near 41 is inflated by a third quarter in which GAAP net income fell to about $210 million on items excluded from adjusted results; on forward estimates (about $11.61 of EPS for 2027) the multiple is near 23. That is a premium to where the stock traded early in 2026, after a roughly 30% year-to-date rise, and the dividend yield has compressed to about 2.0%. The market is paying for steady mid single-digit growth, high margins, strong cash generation and a raised 2026 outlook, still with some discount for litigation and patent-cliff overhangs; figures are approximate as of November 20, 2026.

URGN. There is no meaningful trailing P/E because UroGen is still loss-making over the last twelve months, roughly ~$66M of net loss, so the shares are framed on sales multiples and on how quickly the Zusduri ramp closes the gap. About ~$1.55B of market value against ~$250M of trailing revenue is roughly 6x sales, and analysts' 2027 estimates (revenue near $535M, EPS near $2.50) put the forward P/E around 13x, which is what the stock is being priced on; the mean analyst target of ~$60.71 from seven analysts sits well above the price. Debt and the RTW obligation still matter here, unlike for a cash-rich clinical-stage biotech, and the next data point is fourth-quarter results in early 2027.

Headline figures (approximate, November 2026): JNJ shows revenue (ttm) ~$99 billion, q3 2026 sales ~$25.4 billion (+~6% YoY), q3 2026 adjusted eps $2.59 (vs ~$2.52 est.), operating margin ~27%; URGN shows market cap ~$1.55B (~$31.68 per share, November 20, 2026), revenue (ttm) ~$250M (latest quarter up ~224% year over year), revenue (q3 2026) ~$89.0M (Zusduri ~$68.0M, Jelmyto ~$21.0M), net loss (q3 2026 / ttm) ~$1.5M (~$0.03 per share, vs ~$0.11 profit expected) / ~$66M.

The bottom line: JNJ vs URGN

JNJ and URGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined JNJ and URGN exposure against your real portfolio. It is not an investment adviser.

Wondering how JNJ or URGN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Johnson & Johnson

Ask Walnut's AI anything about JNJ and see how it fits what you own.

FAQ

What is the difference between JNJ and URGN?

+

Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). UroGen Pharma (Nasdaq: URGN) develops and sells drugs that treat urothelial cancers without surgery. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is JNJ or URGN the better stock?

+

Neither is universally better. JNJ is the larger incumbent; URGN is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, JNJ or URGN?

+

On forward P/E (as of November 2026), JNJ trades at 23.29x and URGN at 12.67x, so URGN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both JNJ and URGN?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of JNJ vs URGN?

+

JNJ: J&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue. Drug pricing pressure, including US government negotiation of certain drug prices, can weigh on margins. The company also faces significant legal liability, most notably ongoing litigation related to talc-based products, which has created uncertainty and large potential settlements. MedTech competes in tough device markets and is exposed to hospital budgets and procedure volumes. Regulatory, clinical-trial, and product-safety risks are inherent to healthcare. International pricing pressure weighed on third-quarter 2026 results, and large items outside adjusted earnings cut GAAP net income to about $210 million that quarter. Growth is steady rather than rapid, yet after a roughly 33% one-year rise the stock trades near 23 times forward earnings, so valuation now leaves less cushion than it did when J&J traded in the mid-teens. URGN: The company still runs a shareholders' deficit of ~$125M, with ~$90.5M of cash and marketable securities against ~$196M of term debt and a prepaid forward obligation to RTW, and liquidity fell from ~$120.5M at the end of 2025. Its own filings frame going-concern as dependent on Jelmyto and Zusduri cash inflows plus the ability to raise capital, though management states it has funding beyond one year, and at-the-market equity capacity makes dilution an available lever. Concentration risk is severe: two products, one delivery technology, and one therapeutic area, with Zusduri now about three quarters of revenue after roughly a year on the market. A launch curve this steep can flatten quickly if reimbursement, site onboarding, or repeat prescribing stalls, and sequential growth already slowed from ~73% to ~35% in the third quarter. Competition is arriving from several directions at once, including newly approved intravesical therapies in adjacent bladder cancer settings, competing clinical trials that management says are pulling Jelmyto patient starts, and cheap compounded chemotherapy regimens that urology practices already use. Jelmyto faces generic entry in September 2030 and Zusduri loses regulatory exclusivity in June 2028, so the patent running to 2044 has to hold up to be worth what the market is assigning it. The share price itself has become a risk signal: the stock fell about 32% over the three months to November 20, 2026, from a 52-week high of about $50.81, and dropped after the third-quarter EPS miss, while options implied volatility has been rising.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell JNJ or URGN; figures are approximate and dated (as of November 2026). Verify current data before investing.